Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Gene Therapy Market to Hit USD 36.55 Billion by 2032 with 19.4% CAGR | MarketsandMarkets™.

This image opens in the lightbox

News provided by

MarketsandMarkets

20 Feb, 2025, 15:30 GMT

Share this article

Share toX

Share this article

Share toX

DELRAY BEACH, Fla., Feb. 20, 2025 /PRNewswire/ -- The global Gene Therapy market, valued at US$7.21 billion in 2023, is forecasted to grow at a robust CAGR of 19.4%, reaching US$8.85 billion in 2024 and an impressive US$36.55 billion by 2032. Market growth is attributed to factors such as the growing demand for curative therapies for genetic disorders, rare diseases, and specific types of cancer, robust clinical trial pipeline for gene therapy and increasing investments in gene therapy research. For instance, according to M&M, around 19 gene therapy products are expected to be launched between 2026 to 2032, and which will contribute closely to 25% of the 36.55 B market in 2032.

However, high cost of gene therapy products and Complex regulatory frameworks and ethical concerns regarding genetic modifications are expected to hinder the market growth over the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857962

Browse in-depth TOC on "Gene Therapy Market"

660 - Tables
60 - Figures
433 - Pages

Based on therapy type, the gene therapy market is segmented into gene silencing therapy, cell replacement therapy, gene augmentation therapy and other therapies. The gene silencing therapy segment accounted for the largest share of the gene therapy market. This can be owing to the availability of many approved and commercialized gene therapies employing gene silencing mechanism of action in the current market, effectiveness of gene silencing mechanism against major indications in neurology.

Among vector segment, the gene therapy market is segmented into viral vectors and non-viral vector. The viral vectors segment accounted for the largest share of the gene therapy market. The large share of this segment can be owing to the the high market penetration of viral vector-based gene therapies and advantages of viral vectors over non-viral vectors.

Among scale of operation segment, the gene therapy market is segmented into manufacturing-scale operations, pilot-scale operations, and R&D-scale operations. The manufacturing-scale operations segment accounted for the largest share of the gene therapy market. The large share of this segment can be owing to the growth in biologics and biosimilar manufacturing. Additionally, increasing number of biopharmaceuticals receiving regulatory approvals for production and the launch of biosimilars in the market is propelling the growth of the segment in gene therapy market.

Among gene type segment, the gene therapy market is segmented into deficiency, receptors, antigen, cytokine, tumour suppressor, other gene. The deficiency segment accounted for the largest share of the gene therapy market. Increasing number of prevalence of rare genetic disorders caused due to deficiency of particular gene type, and approval of gene therapies for such rare diseases are the major factors driving the growth of this segment.

Based on region, The gene therapy market is segmented by region into six key regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2023, North America led the market, followed by Europe in second place and the Asia Pacific in third. North America is expected to experience the highest growth rate during the forecast period. Factors driving this regional growth include the expansion of R&D activities, rising demand for gene therapies, increasing fundings and investments in biopharmaceutical industries for conducting extensive research on advanced therapies.

In addition, the US accounted for the largest market share in the North American gene therapy market. Major share of the country is determined by factors like well-established pharmaceutical and biotechnology sector, rising approvals of innovative gene therapies, increasing incidences of diseases like cancer along with high funding for the life sciences research are also contributing to the major share of the country. For example, according to the National Cancer Institute, there were nearly 2 million people who were suffering from cancer cases in 2023 in US. The current treatment options will cater to the unmet demands if gene therapies are employed. Since advanced manufacturing technologies is used in the R&D and production of gene therapies, it is likely that these factors will create a large number of opportunities for the growth of the gene therapy market.

Europe is the second largest market after North America. The availability of government funding, growth in the biotechnology and pharmaceutical sectors, and the rise in the number of conferences, symposia, seminars, trade fairs, annual events, and workshops being organized in Europe that focus on creating awareness about gene therapies and are expected to drive the growth of the market in the region. These factors help increase awareness about current technological advancements and aid in the discussion of various challenges and opportunities prevailing in the industry. Such events also offer market players the opportunity to showcase their products and communicate with stakeholders while helping scientists and researchers to exchange experiences. According to the Alliance for Regenerative Medicine (ARM), a global advocate for regenerative and advanced therapies, out of 843 regenerative medicine companies globally, Europe houses 234.

Moreover, in 2023, the Asia Pacific is third largest market for gene therapies. This surge in the regional market is attributed to various factors such as government backing for advanced manufacturing technologies and innovative gene therapies, expansion initiatives by key market players in emerging Asian economies, heightened therapy manufacturing capacities of major companies, increased research and development investments by biotechnology and pharmaceutical firms, collaborative ventures in bioprocessing, a growing elderly population, amplified focus on regenerative medicine research, and the upsurge in preclinical/clinical research particularly in China and India, is expected to drive the gene therapy market in Asia Pacific.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=122857962

Biogen Inc. (US), Novartis AG (Switzerland), and Alnylam Pharmaceuticals, Inc. (US) are holding significant global market share, and the global Gene Therapy market is highly consolidated.

Biogen Inc. (US)

In 2023, Biogen had the largest share in gene therapy market. Biogen is a biotechnology company specializing in developing therapies for diseases like multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Stronge pipeline aims to develop novel therapeutics with potential across multiple therapeutic areas, including neurology, neuropsychiatry, specialty immunology and rare diseases. High investments on R&D for novel therapies like gene therapies soar their credibility in global market. Biogen spent USD 2.46 billion on R&D in 2023. Additionally, by having a strong distribution channel and solid pipeline products enables Biogen to gain competitive share in the global gene therapy market.

Novartis AG (Switzerland)

Novartis is one of the leading players in gene therapy market. The company's products such as Zolgensma (onasemnogene abeparvovec-xioi) are major contributors to the gene therapy market. The company also has a strong geographic presence with distribution channels across North America, Europe, Asia Pacific, Latin America, and Africa. The company is focusing on inorganic growth strategies such as acquisition and collaboration for the development of innovative gene therapy products which supports its leading position in the gene therapy market. For instance, in November 2024, Novartis acquired Kate Therapeutics, gaining access to the latter's proprietary DELIVER capsid engineering platform, which is expected to help with potent and selective gene therapy development.

Alnylam Pharmaceuticals, Inc. (US)

Alnylam is one of the leading players in the gene therapy market. The company has a broad pipeline, including four approved products and multiple late and early-stage investigational RNAi therapeutics. The company focused on four major therapeutic areas such as Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases, and CNS/Ocular Diseases. The company is focusing on collaboration and acquisition to develop the innovative therapies. For instance, in July 2023, Alnylam Pharmaceuticals signed an agreement with Roche to develop and commercialize zilebesiran, Alnylam's investigational RNAi therapeutic for treating hypertension, which is currently in Phase 2 of development.

For more information, Inquire Now!

Related Reports:

Biologics Safety Testing Market

Viral Vector & Plasmid DNA Manufacturing Market

Bioinformatics Market

Next Generation Sequencing Market

Stem Cell Therapy Market

Get access to the latest updates on Gene Therapy Companies and Gene Therapy Market Size

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg 

Modal title

Also from this source

MarketsandMarkets' 360Quadrants Recognizes Top Startups and SMEs in the Green Technology and Sustainability Quadrant Report 2025

MarketsandMarkets' 360Quadrants Recognizes Top Startups and SMEs in the Green Technology and Sustainability Quadrant Report 2025

360Quadrants has released its latest Green Technology and Sustainability Startups/SMEs Companies Assessment, 2025, recognizing key players, including ...

Laboratory Information Management System Market worth US$5.19 billion by 2030 with 12.5% CAGR | MarketsandMarkets™

Laboratory Information Management System Market worth US$5.19 billion by 2030 with 12.5% CAGR | MarketsandMarkets™

The global Laboratory Information Management System Market, valued at US$2.54 billion in 2024, is forecasted to grow at a robust CAGR of 12.5%,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.